ALLERGAN AMO ARRAY FOLDABLE INTRAOCULAR LENS SHOULD BE APPROVED AS BIFOCAL IOL CONTINGENT ON LABELING CHANGES, OPHTHALMIC PANEL SAYS IN 10-1 VOTE
This article was originally published in The Gray Sheet
Executive SummaryAllergan's AMO Array model SA40N posterior chamber intraocular lens should be designated "bifocal" instead of "multifocal," FDA's Ophthalmic Devices Panel said July 10 in recommending approval of the IOL contingent on several labeling changes.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.